These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9676786)

  • 1. Soluble CD44 isoform variant-5 (sCD44v5): a new serum marker in rheumatoid arthritis?
    Haberhauer G; Kittl EM
    J Rheumatol; 1998 Jul; 25(7):1442-4. PubMed ID: 9676786
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased serum levels of soluble CD44-isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis.
    Haberhauer G; Kittl EM; Skoumal M; Hübl W; Wagner E; Bayer PM; Bauer K; Dunky A
    Acta Med Austriaca; 1997; 24(1):23-5. PubMed ID: 9150806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum soluble CD44 isoform variant 5 level in patients with seropositive rheumatoid arthritis treated with cyclosporin A].
    Feyertag J; Haberhauer G; Skoumal M; Kittl EM; Bauer K; Dunky A
    Acta Med Austriaca; 2000; 27(5):156-9. PubMed ID: 11261266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of soluble CD44 in primary Sjögren's syndrome.
    Levesque MC; Mackin DA; Fleming JA; St Clair EW
    J Rheumatol; 2000 Jun; 27(6):1444-9. PubMed ID: 10852268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD44-isoform variant-5 (sCD44v5) in psoriatic arthritis.
    Haberhauer G; Kittl EM; Bauer K; Skoumal M; Feyertag J; Dunky A
    Clin Exp Rheumatol; 1998; 16(6):766-7. PubMed ID: 9844784
    [No Abstract]   [Full Text] [Related]  

  • 7. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion.
    Fujikawa K; Kawakami A; Tamai M; Uetani M; Takao S; Arima K; Iwamoto N; Aramaki T; Kawashiri S; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Aoyagi K; Eguchi K
    J Rheumatol; 2009 Jun; 36(6):1126-9. PubMed ID: 19447929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis.
    Kittl EM; Haberhauer G; Ruckser R; Selleny S; Rech-Weichselbraun I; Hinterberger W; Bauer K
    Rheumatol Int; 1997; 16(5):181-6. PubMed ID: 9032816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration of soluble CD44 standard and soluble CD44 variant V5 in the serum of patients with malignant bone tumors.
    Holzer G; Kittl E; Pfandelsteiner T; Trieb K; Kotz R
    Med Pediatr Oncol; 2003 Jan; 40(1):64-5. PubMed ID: 12426692
    [No Abstract]   [Full Text] [Related]  

  • 12. [Study of serum glycoproteins in rheumatoid arthritis].
    Bosković D; Baltazarević V; Mihajlović D; Janković N; Kojović Z
    Reumatizam; 1978; 25(2):44-9. PubMed ID: 653145
    [No Abstract]   [Full Text] [Related]  

  • 13. Rheumatoid arthritis: correlation between rheumatoid factor levels and CA-125 tumour marker elevation.
    Tsavaris N; Mavragani CP; Pikazis D
    Ann Rheum Dis; 2007 Jul; 66(7):980. PubMed ID: 17576786
    [No Abstract]   [Full Text] [Related]  

  • 14. Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes.
    Loeffler-Ragg J; Steurer M; Ulmer H; Skvortsov S; Kircher B; Herold M; Zwierzina H; Stauder R
    Leukemia; 2006 Nov; 20(11):2064-7. PubMed ID: 16990777
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelial function and novel adhesion molecule CD44 in kidney allograft recipients.
    Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
    Transplant Proc; 2008 Dec; 40(10):3470-3. PubMed ID: 19100415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of reputed tumor-associated soluble CD44 isoforms (v5 and v6) in smokers are dose related and decline on smoking cessation.
    Scott DA; Stapleton JA; Palmer RM; Wilson RF; Sutherland G; Coward PY; Gustavsson G; Odell EW; Poston RN
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1211-4. PubMed ID: 11097229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Soluble adhesion molecules (P-selectin, ICAM-1 and ICAM-3) in rheumatoid arthritis].
    Nasonov EL; Samsonov MIu; Tilz GP; Nikiforova EL; Chichasova NV; Imametdinova GR; Ilich-Stoianovich O; Baranov AA; Fuchs D; Nasonova VA
    Ter Arkh; 1999; 71(5):17-20. PubMed ID: 10399223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis.
    Nikolaisen C; Rekvig OP; Nossent HC
    Scand J Rheumatol; 2007; 36(2):97-100. PubMed ID: 17476614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer.
    Masson D; Denis MG; Denis M; Blanchard D; Loirat MJ; Cassagnau E; Lustenberger P
    Br J Cancer; 1999 Aug; 80(12):1995-2000. PubMed ID: 10471052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.